SCHEMBL4151574

SCHEMBL4151574

CC=NOc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA4 P22748 1/20 0.42
LTA4H P09960 3/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 3/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KCNA3 P22001 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HTT P42858 2/20 0.33
ALDH1A1 P00352 2/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
PKM P14618 1/20 0.32
TRPA1 O75762 1/20 0.32
CA5A P35218 1/20 0.32
CA5B Q9Y2D0 1/20 0.32
PGR P06401 1/20 0.31
HPGD P15428 1/20 0.31
CES2 O00748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14667490 1.00 CA4 (0.42) CA4LTA4HTSHRLMNATDP1
SCHEMBL22129143 0.79 LTA4H (0.43) CA4LTA4HTSHRLMNATDP1
SCHEMBL27016003 0.76 CA4 (0.44) CA4LTA4HTSHRLMNATDP1
SCHEMBL4155588 0.75 LTA4H (0.39) CA4LTA4HTSHRLMNATDP1
SCHEMBL22485139 0.75 LTA4H (0.39) CA4LTA4HTSHRLMNATDP1
SCHEMBL6193818 0.75 LTA4H (0.39) CA4LTA4HTSHRTDP1L3MBTL1
SCHEMBL16760862 0.75 CA4 (0.42) CA4LTA4HTSHRLMNAL3MBTL1
SCHEMBL21428538 0.75 CA4 (0.37) CA4LTA4HTSHRLMNAL3MBTL1
SCHEMBL9945371 0.75 LTA4H (0.38) CA4LTA4HTSHRLMNAL3MBTL1
SCHEMBL9944297 0.75 MAPK1 (0.38) CA4LTA4HTSHRLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718653-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY Ligand Pharmaceuticals Inc. (US) 2006-11-08 EP claimed
WO-2005082909-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY LIGAND PHARMACEUTICALS INCORPORATED (US) 2005-09-09 WO claimed
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-04-23 US disclosed
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-12-06 US disclosed
CN-101027401-A Method for preparing low molecular weight organic compound in cell POALIS AS (DK) 2007-08-29 CN disclosed
EP-1718653-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY Ligand Pharmaceuticals Inc. (US) 2006-11-08 EP disclosed
WO-2005082909-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY LIGAND PHARMACEUTICALS INCORPORATED (US) 2005-09-09 WO disclosed
CN-1060652-A OXAMIDES SMITHKLINE BEECHAM CORP (US) 1992-04-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods NR3C1, NR3C2, MC2R CA4 3545/4885LTA4H 399/4885TSHR 244/4885
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods NR3C1, NR3C2, MC2R CA4 3545/4885LTA4H 399/4885TSHR 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.